A congressional ethics watchdog released a report Thursday that found Rep. Chris Collins (R-NY) may have broken ethics rules and federal law with actions he took as a board member of the biotech firm Innate Immunotherapeutics.

The independent Office for Congressional Ethics (OCE), which may investigate allegations against lawmakers and refer its findings to the House Ethics Committee, found there is “substantial reason to believe” Collins shared nonpublic information about the purchase of Innate stock with investors and that he took official actions to help Innate: two National Institutes of Health employees told OCE that Collins asked an NIH employee to help Innate with a clinical trial.

It asked that the House Ethics Committee further review those two actions. The watchdog said it did not find substantial reason to believe that Collins purchased discounted stock, however.

The House Ethics panel said Thursday that it was again extending a review of the allegations against Collins.

The committee first extended its review following a report that Collins purchased Innate stock while the Food and Drug Administration was considering whether to approve a drug made by the company. Collins also introduced an amendment to a House bill related to FDA drug approval that would impact Innate, according to the Daily Beast’s reporting.

Former Health and Human Services Secretary Tom Price did not cooperate with the OCE investigation, according to the watchdog’s report. The watchdog recommended the House Ethics Committee subpoena Price, who said in his confirmation hearing that he purchased Innate stock after hearing about it from Collins.

Correction: The initial version of this post incorrectly referred to the Food and Drug Administration as the Federal Drug Administration.